Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease

• Steven Holshouser,
• Rebecca Cafiero,
• Mayra Robinson,
• Joy Kirkpatrick,
• Robert A. Casero,
• Hyacinth I. Hyacinth,
• Patrick M. Woster

Affiliations

Steven Holshouser

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, United States

Rebecca Cafiero

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, United States

Mayra Robinson

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, United States

Joy Kirkpatrick

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, United States

Robert A. Casero

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, United States

Hyacinth I. Hyacinth

Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, United States

Patrick M. Woster

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, United States